Ilaris (canakinumab) is a prescription drug that’s used to treat certain conditions such as Still disease. Ilaris comes as a liquid solution that a healthcare professional will give as an injection ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Novartis’ Ilaris injection for the treatment of active and adult-onset Still’s disease, ...

Ilaris® (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection(1) In ...

Ilaris (canakinumab) can cause side effects that range from mild to serious. More common side effects include weight gain and the common cold. If side effects from Ilaris become difficult to tolerate, ...

The FDA has approved Ilaris (canakinumab; Novartis) for the treatment of active Still disease, including adult-onset Still disease. The Food and Drug Administration (FDA) has approved Ilaris ...

Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments Ilaris® is the first biologic approved in the EU for ...

New biological therapy Ilaris® approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease Phase III data show rapid and sustained remission in more than 90% ...

Jazz Pharmaceuticals and PharmaMar’s Zepzelca (lurbinectedin) has been granted accelerated approval for adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed during ...

ZURICH, May 10 (Reuters) - Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis. Ilaris inhibits ...

EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday. Novartis ...